AstraZeneca PLC (AZN)vsSol Gel Technologies Ltd (SLGL)
AZN
AstraZeneca PLC
$193.92
+2.92%
HEALTHCARE · Cap: $292.10B
SLGL
Sol Gel Technologies Ltd
$68.54
-13.46%
HEALTHCARE · Cap: $99.10M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 245352% more annual revenue ($58.74B vs $23.93M). AZN leads profitability with a 17.4% profit margin vs -14.2%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SLGL
Hold40
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.8%
Fair Value
$306.07
Current Price
$193.92
$112.15 discount
Intrinsic value data unavailable for SLGL.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 65.1%
Revenue surging 217.7% year-over-year
Earnings expanding 487.6% YoY
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Smaller company, higher risk/reward
ROE of -10.2% — below average capital efficiency
Currently unprofitable
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : SLGL
The strongest argument for SLGL centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 217.7% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : SLGL
The primary concerns for SLGL are Market Cap, Return on Equity, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a value stock while SLGL is a hypergrowth play — different risk/reward profiles.
SLGL carries more volatility with a beta of 1.38 — expect wider price swings.
SLGL is growing revenue faster at 217.7% — sustainability is the question.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (64/100 vs 40/100), backed by strong 17.4% margins. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Sol Gel Technologies Ltd
HEALTHCARE · BIOTECHNOLOGY · USA
Sol-Gel Technologies Ltd., a specialty clinical-stage pharmaceutical company, is focused on developing and commercializing topical dermatological pharmaceuticals based on its Israel-patented microencapsulation delivery system. The company is headquartered in Ness Ziona, Israel.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?